

REMARKS

Claims 1, 6, 8, 9, 11, 12, and 15-28 are pending in the present application.

The rejections of Claims 1, 9, and 14 under 35 U.S.C. §112, first paragraph (written description and enablement), are obviated by amendment.

Applicants make no statement with respect to the propriety of these grounds of rejection and in no way acquiesce to the same. Nonetheless, to expedite examination, Applicants have amended Claim 1 to incorporate a list of enzyme alternatives based on those set forth in allowable Claims 6, 8, 11, and 13. Since the list of enzyme alternatives set forth in Claims 6, 8, 11, and 13 are recognized as being adequately described and enabled, so to is amended Claim 1. Similarly, Claims 9 and 14 depend from Claim 1 and, therefore, these claims are also adequately described and enabled.

Withdrawal of these grounds of rejection is requested.

Applicants submit that the present application is in condition for allowance. Early notification to this effect is respectfully requested.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.



Stephen G. Baxter, Ph.D.  
Registration No. 32,884

Vincent K. Shier, Ph.D.  
Registration No. 50,552

Customer Number

22850

Tel: (703) 413-3000  
Fax: (703) 413-2220  
(OSMMN 08/03)